ADENOSINE THERAPEUTICS, LLC

Company Information
Address 310 FOURTH STREET NE
SUITE 201
CHARLOTTESVILLE, VA, 22902


Information

DUNS: 1016760

# of Employees: N/A


Ownership Information

HUBZone Owned: N

Socially and Economically Disadvantaged: N

Woman Owned: N



Award Charts




Award Listing

  1. Adenosine A2A receptor antagonists for the treatment of cocaine addiction

    Amount: $104,783.00

    DESCRIPTION (provided by applicant): Selective antagonists of A2A adenosine receptors (A2AR) are thought to have potential for the treatment of addictive disorders, including cocaine addiction. This p ...

    SBIRPhase I2007Department of Health and Human Services
  2. Antagonists of A2B Adenosine Receptors for Asthma

    Amount: $1,440,610.00

    DESCRIPTION (provided by applicant): This is a Phase II SBIR proposal to develop a new therapy for the treatment of asthma. The desired outcome will be the identification of a therapeutic candidate to ...

    SBIRPhase II2006Department of Health and Human Services
  3. A2A Adenosine Receptors and Equine Sepsis

    Amount: $296,000.00

    Endotoxemia (Sepsis) affects horses of all breeds and ages and is the leading causes of death in adult horses and foals. Consequently, its economic impact on the equine industry in the United States i ...

    SBIRPhase II2006Department of Agriculture
  4. A2A AR Agonists as Adjunct Therapy Against S. aureus Sepsis

    Amount: $132,798.00

    DESCRIPTION (provided by applicant): This is a phase I STTR application to study the efficacy of selective adenosine A2A receptor (A2AR) agonists developed in the laboratories of Adenosine Therapeutic ...

    STTRPhase I2006Department of Health and Human Services
  5. A2a AR Agonists for Rheumatoid Arthritis

    Amount: $137,603.00

    DESCRIPTION (provided by applicant): This is the first revision of a phase I STTR proposal to develop new therapies for the treatment of rheumatoid arthritis (RA). It is collaboration between a biotec ...

    STTRPhase I2006Department of Health and Human Services
  6. Safety of A2A Adenosine Agonist for Treatment of Sepsis

    Amount: $1,276,772.00

    DESCRIPTION (provided by applicant): ATL146e is a synthetic small molecule developed by Adenosine Therapeutics, LLC (ATL) that acts as a selective agonist of the adenosine A2A receptor. ATL146e, steri ...

    STTRPhase I2006Department of Health and Human Services
  7. A2a Adenosine Agonist Cardiac Reperfusion Injury

    Amount: $288,277.00

    DESCRIPTION (provided by applicant): Founded in 1999, Adenosine Therapeutics LLC (ATL) is a drug discovery and development company that has developed a family of potent and selective adenosine A2A re ...

    SBIRPhase I2005Department of Health and Human Services
  8. A2a Adenosine Agonists for Diabetic Nephropathy

    Amount: $147,326.00

    DESCRIPTION (provided by applicant): Diabetic nephropathy (DN) accounts for approximately 40% of the cases of renal failure requiring dialysis or transplantation. Moreover, diabetic nephropathy is ass ...

    STTRPhase I2005Department of Health and Human Services
  9. A2a Adenosine Blockers for Parkinson's Disease

    Amount: $139,176.00

    DESCRIPTION (PROVIDED BY APPLICANT): Selective antagonists of A2A adenosine receptors have proven to be effective for the treatment of Parkinson's disease (PD) both in animal models and in a human tri ...

    STTRPhase I2005Department of Health and Human Services
  10. Novel A2A Adenosine Agonists in Vascular Protection

    Amount: $1,247,577.00

    DESCRIPTION (provided by applicant): This is a phase II SBIR proposal to develop a new drug eluting stent to prevent restenosis. It is a 3-way collaboration between Adenosine Therapeutics, LLC, Setago ...

    STTRPhase II2004Department of Health and Human Services

Agency Micro-sites

US Flag An Official Website of the United States Government